A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL

Trial Profile

A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Bendamustine; Rituximab
  • Indications B cell lymphoma; MALT lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Jul 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Nov 2016, as reported by ClinicalTrials.gov.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology (n = 15).
    • 01 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top